PMP22

Across TCGA pan-cancer cohorts, PMP22 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PMP22 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PMP22 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PMP22 expression acts as an unfavorable survival marker.

COAD, BLCA, and KIRC are the cancer types where PMP22 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.130	0.685	<.001	30	view →
BLCA	OS	Median	All	0.188	0.710	.004	15	view →
KIRC	OS	Median	All	0.127	0.874	<.001	12	view →
UCEC	OS	Median	IV	0.066	0.755	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PMP22–COAD (OS)

Open the COAD breakdown →